Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.
A 43-year-old woman with multiple sclerosis (MS) was treated with pulsed methylprednisolone and interferon beta at a hospital. Four weeks after initiating treatment, liver dysfunction occurred and she was referred and admitted to our hospital. Clinical and laboratory findings were consistent with and fulfilled the criteria for drug-induced hepatitis, but not for autoimmune hepatitis (AIH). She was successfully treated with corticosteroids. As ataxia developed after 1 year, she was treated with pulsed methylprednisolone for 3 d, then readmitted to our hospital when liver dysfunction occurred. Clinical and laboratory findings led to the diagnosis of AIH. To the best of our knowledge, this is the second case of AIH developed after pulsed methylprednisolone for MS.
Takahashi
Atsushi
A
Department of Internal Medicine II, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Japan. junior@fmu.ac.jp
Kanno
Yukiko
Y
Takahashi
Yuta
Y
Sakamoto
Natsumi
N
Monoe
Kyoko
K
Saito
Hironobu
H
Abe
Kazumichi
K
Yokokawa
Junko
J
Irisawa
Atsushi
A
Ohira
Hiromasa
H
D000328:Adult; D005260:Female; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D007371:Interferon-gamma; D008775:Methylprednisolone